Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accounts Payables: 2020-2025

Historic Accounts Payables for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $12.2 million.

  • Mirum Pharmaceuticals' Accounts Payables rose 27.47% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 27.47%. This contributed to the annual value of $14.6 million for FY2024, which is 97.11% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Accounts Payables stood at $12.2 million for Q3 2025, which was down 31.09% from $17.7 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Accounts Payables high stood at $17.7 million for Q2 2025, and its period low was $4.9 million during Q1 2022.
  • Moreover, its 3-year median value for Accounts Payables was $11.6 million (2025), whereas its average is $11.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 190.89% in 2021, then slumped by 31.87% in 2024.
  • Mirum Pharmaceuticals' Accounts Payables (Quarterly) stood at $9.2 million in 2021, then fell by 5.19% to $8.7 million in 2022, then declined by 14.66% to $7.4 million in 2023, then spiked by 97.11% to $14.6 million in 2024, then increased by 27.47% to $12.2 million in 2025.
  • Its Accounts Payables was $12.2 million in Q3 2025, compared to $17.7 million in Q2 2025 and $11.6 million in Q1 2025.